Objective: This meta-analysis was performed to compare the efficacy and toxicity of cetuximab plus concurrent chemo-radiotherapy (CCRT) with CCRT alone for advanced nasopharyngeal carcinoma (NPC). Methods: The related literature were retrieved and reviewed from the followed electronic databases: PubMed, The Oxford Journals Collection, Elsevier Clinicalkey and Web of Science, Chinese National Knowledge Infrastructure (CNKI), WANFANG DATA, China Biology Medicine (CBM), etc. Review manager 5.0 software was applied for statistical analysis. Results: From 2013 to 2016, a total of eight randomized control trials with 371 patients were recruited for analysis. Compared with CCRT alone, cetuximab combined with CCRT revealed significant improvement of complete response (CR), objective response rate (ORR) and disease control rate (DCR). Meanwhile, the rates of stable disease (SD) and progression disease (PD) were both declined dramatically. However, adding cetuximab was associated with higher incidence of rash and radiation-induced laryngopharyngitis. There was no significant difference of other side effects between two groups. Conclusion: Cetuximab plus CCRT can improve CR, ORR and DCR in patients with advanced NPC, and the toxicity profiles are no different except for the incidence of rash and radiation-induced laryngopharyngitis.